Vivitrol Medication Adherence Rates During the COVID-19 Pandemic in An Outpatient Substance Abuse Clinic
No Thumbnail Available
Authors
Meeting name
Sponsors
Date
Journal Title
Format
Paper
Subject
Abstract
The infection caused by a novel coronavirus, serious acute respiratory syndrome coronavirus 2, is known as Coronavirus Disease 2019. The new coronavirus disease 2019 pandemic is placing enormous pressure on global health systems. Recommended strategies to contain the transmission of the infection may negatively impact special patient groups, such as those with a serious substance use disorder who are unable to visit healthcare services for treatment and medication maintenance. A quality improvement project was conducted to determine the effect of COVID-19 on medication adherence rates in patients on Vivitrol for opioid and or alcohol dependence at a substance abuse outpatient clinic in the Midwest. Aggregate data were measured in three cohorts, prior to COVID-19, fall 2020 COVID-19, and 2021 COVID-19. The measurement tool used in this project was a descriptive-analytic tool that helped determine the medication adherence rates, followed by a chi-square test that determined the comparison of the nominal data of the three cohorts. Six months prior to COVID-19, there were 137 participants with an adherence rate of 54%. In fall 2020 COVID-19 there were 41 participants with an adherence rate of 12%. In late 2021 COVID-19, there were 24 participants with an adherence rate of zero percent. The results indicate a significant decrease in participants enrolled in the Vivitrol program along with a decrease in medication adherence rates during the COVID-19 pandemic. Based on the findings, a quality improvement intervention will be proposed to improve Vivitrol medication adherence rates utilizing the Plan-Do-Study-Act, in the second phase of this project.
Table of Contents
DOI
PubMed ID
Degree
D.N.P.
Thesis Department
Rights
Open Access (fully available)